Antioxidants for Pancreatic Functions in Chronic Pancreatitis: A Double-blind Randomized Placebo-controlled Pilot Study. Issue 3 (March 2020)

• Record Type: Journal Article
• Authors: Singh, Namrata; Ahuja, Vineet; Sachdev, Vikas; Upadhyay, Ashish D.; Goswami, Ravinder; Ramakrishnan, Lakshmy; Dwivedi, Supriya; Saraya, Anoop
• Is Part Of: Journal of clinical gastroenterology. Volume 54:Issue 3(2020)
• Publication Date: 2020-03
• Subjects: oxidative stress -- markers of fibrosis -- quality of life -- chronic pancreatitis -- antioxidants; Gastroenterology -- Periodicals; Digestive organs -- Diseases -- Periodicals; Gastroenterology -- Periodicals; Digestive organs -- Diseases; Gastroenterology; Periodicals; Periodicals; 616.33005
• DOI: 10.1097/MCG.0000000000001178
• Languages: English
• ISSNs: 0192-0790

Abstract

Abstract : Background: Antioxidants (AO) supplementation in chronic pancreatitis (CP) has been evaluated for pain. But it is not clear whether AO in CP have an effect on pancreatic functions and other clinical outcomes. We evaluated effect of AO on endocrine function in CP. Materials and Methods: Double-blind placebo (PL)-controlled randomized pilot study on 107 patients with CP assigned to receive daily combined AO or PL for 6 months. Primary outcome was: improvement in endocrine function (Homeostasis Model Assessment-Insulin Resistance). Secondary outcome measures were: improvement in C-peptide, Qualitative Insulin Sensitivity Check Index, exocrine pancreatic function (fecal elastase), surrogate markers of fibrosis (platelet-derived growth factor BB, transforming growth factor-β1, α-smooth muscle actin), quality of life (QOL), pain, nutritional status, markers of oxidative stress (OS), AO status, and inflammation. Results: There was an increase in levels of serum selenium (107.2±26.9 to 109.7±26.9 vs. 104.1±28.6 to 124.0±33.6 μg/L, P =0.022) and serum vitamin E [0.58 (range, 0.27-3.22) to 0.66 (range, 0.34-1.98) vs. 0.63 (range, 0.28-1.73) to 1.09 (range, 0.25-2.91) mg/dL, P =0.001] in the AO than the PL group. However, no significant differences were observed between groups in any of the primary or secondary outcome measures. Conclusions: Supplementation with AO to patients with CP causes a sustained increase in blood levels of AO; however, it has no addition benefit over PL on endocrine and exocrine functions, markers of fibrosis, OS and inflammation, nutritional status, pain and QOL. Further larger studies with adequate sample size are required. Abstract : Supplemental Digital Content is available in the text.